At present, the only wild-type (WT) recombinant IL2 cancer treatment approved for usage is aldesleukin, which is available for metastatic melanoma or renal cell carcinoma (RCC) in several countries worldwide (6). This evidence concerns the gene IL2 and renal cell carcinoma.